Literature DB >> 33881567

Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors.

Roberto Cannella1,2, Emanuele Tabone3, Giorgia Porrello4, Giovanni Cappello3, Cecilia Gozzo5, Lorena Incorvaia4, Giovanni Grignani6, Alessandra Merlini6,7, Lorenzo D'Ambrosio6, Giuseppe Badalamenti8, Daniele Regge3,9, Tommaso Vincenzo Bartolotta4,10.   

Abstract

OBJECTIVES: To investigate the correlation between CT imaging features and risk stratification of gastrointestinal stromal tumors (GISTs), prediction of mutation status, and prognosis.
METHODS: This retrospective dual-institution study included patients with pathologically proven GISTs meeting the following criteria: (i) preoperative contrast-enhanced CT performed between 2008 and 2019; (ii) no treatments before imaging; (iii) available pathological analysis. Tumor risk stratification was determined according to the National Institutes of Health (NIH) 2008 criteria. Two readers evaluated the CT features, including enhancement patterns and tumor characteristics in a blinded fashion. The differences in distribution of CT features were assessed using univariate and multivariate analyses. Survival analyses were performed by using the Cox proportional hazard model, Kaplan-Meier method, and log-rank test.
RESULTS: The final population included 88 patients (59 men and 29 women, mean age 60.5 ± 11.1 years) with 45 high-risk and 43 low-to-intermediate-risk GISTs (median size 6.3 cm). At multivariate analysis, lesion size ≥ 5 cm (OR: 10.52, p = 0.009) and enlarged feeding vessels (OR: 12.08, p = 0.040) were independently associated with the high-risk GISTs. Hyperenhancement was significantly more frequent in PDGFRα-mutated/wild-type GISTs compared to GISTs with KIT mutations (59.3% vs 23.0%, p = 0.004). Ill-defined margins were associated with shorter progression-free survival (HR 9.66) at multivariate analysis, while ill-defined margins and hemorrhage remained independently associated with shorter overall survival (HR 44.41 and HR 30.22). Inter-reader agreement ranged from fair to almost perfect (k: 0.32-0.93).
CONCLUSIONS: Morphologic contrast-enhanced CT features are significantly different depending on the risk status or mutations and may help to predict prognosis. KEY POINTS: • Lesions size ≥ 5 cm (OR: 10.52, p = 0.009) and enlarged feeding vessels (OR: 12.08, p = 0.040) are independent predictors of high-risk GISTs. • PDGFRα-mutated/wild-type GISTs demonstrate more frequently hyperenhancement compared to GISTs with KIT mutations (59.3% vs 23.0%, p = 0.004). • Ill-defined margins (hazard ratio 9.66) were associated with shorter progression-free survival at multivariate analysis, while ill-defined margins (hazard ratio 44.41) and intralesional hemorrhage (hazard ratio 30.22) were independently associated with shorter overall survival.

Entities:  

Keywords:  Gastrointestinal stromal tumors; Mutation; Progression-free survival; Survival analysis; Tomography, X-ray computed

Year:  2021        PMID: 33881567     DOI: 10.1007/s00330-021-07961-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  1 in total

Review 1.  Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response.

Authors:  Federica Vernuccio; Adele Taibbi; Dario Picone; Ludovico LA Grutta; Massimo Midiri; Roberto Lagalla; Giuseppe Lo Re; Tommaso Vincenzo Bartolotta
Journal:  Anticancer Res       Date:  2016-06       Impact factor: 2.480

  1 in total
  2 in total

1.  Malignancy risk of gastrointestinal stromal tumors evaluated with noninvasive radiomics: A multi-center study.

Authors:  Yun Wang; Yurui Wang; Jialiang Ren; Linyi Jia; Luyao Ma; Xiaoping Yin; Fei Yang; Bu-Lang Gao
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

2.  Building Radiomics Models Based on Triple-Phase CT Images Combining Clinical Features for Discriminating the Risk Rating in Gastrointestinal Stromal Tumors.

Authors:  Meihua Shao; Zhongfeng Niu; Linyang He; Zhaoxing Fang; Jie He; Zongyu Xie; Guohua Cheng; Jian Wang
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.